Lynparza Tablets 120 x 100mg(olaparib)

Reference priceRUB ₽57,750.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Lynparza
Manufacturer	AstraZeneca/Merck
Prescription required	Yes

Description

Lynparza Tablets 120 x 100mg(olaparib) is a medicine catalog record in the MediPriceHub database. Active ingredient: olaparib. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: AstraZeneca/Merck. Therapeutic category: Medicine Library > Oncology Medicines > Ovarian cancer drugs. Pack information: 100 / 120. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer Breast cancer Pancreatic cancer Prostate cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnost

How to Use

Use olaparib under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: olaparib. Pack size: 100 / 120. Pack unit: bottle. Manufacturer: AstraZeneca/Merck. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Ovarian cancer drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.

Эта информация носит справочный характер. Перед применением лекарства проконсультируйтесь с медицинским специалистом.